Group 1 - The core point of the article is the successful approval and registration of Suzhou Fengbei Biotechnology Co., Ltd.'s initial public offering (IPO) of A-shares on the Shanghai Stock Exchange, with the underwriting by Guotai Junan Securities Co., Ltd. [1] - The total number of shares for this issuance is set at 35.9 million, with an initial strategic placement of 7.18 million shares, accounting for 20% of the total issuance [2] - The final strategic placement was adjusted to 4.083297 million shares, which is 11.37% of the total issuance, with the difference being allocated to offline issuance [2] Group 2 - The issuance price is set at 24.49 yuan per share, with the online offering of 11.488 million shares scheduled for October 27, 2025 [2] - The initial effective subscription multiple for the online offering was 8,814.92 times, leading to the activation of a mechanism to adjust the allocation between offline and online offerings [3] - After the adjustment, the final allocation resulted in 760,170.3 thousand shares for offline issuance and 2,421,500 shares for online issuance, with the online issuance accounting for 76.11% of the adjusted total [3] Group 3 - Investors are required to fulfill their payment obligations by October 29, 2025, with specific instructions for both offline and online investors regarding the payment process [4] - If the total number of shares subscribed by offline and online investors does not meet 70% of the adjusted total issuance, the offering will be suspended [5] - There are restrictions on the resale of 10% of the shares allocated to offline investors for a period of six months from the date of listing [5] Group 4 - The strategic placement process has concluded successfully, with all participating investors fulfilling their payment commitments by the specified deadline [8] - The final results of the strategic placement and the online lottery for shares will be announced following the draw on October 28, 2025 [10][11] - The offline issuance saw a total of 7,490,110 thousand shares subscribed, with the initial allocation process adhering to the announced guidelines [12][13]

Core Points - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) of RMB ordinary shares (A-shares) and listing on the main board from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The total number of shares for this issuance is set at 35.9 million, with an initial strategic placement of 7.18 million shares, accounting for 20% of the total issuance [2] - The final strategic placement quantity is 4.083297 million shares, which is 11.37% of the total issuance, with the difference being allocated to offline issuance [2] Issuance Structure - The issuance will combine strategic placement, offline pricing for qualified investors, and online pricing for public investors holding non-restricted A-shares and depository receipts [1] - After the strategic placement adjustment, the offline issuance will consist of 20.328703 million shares (63.89% of the remaining shares), while the online issuance will consist of 11.488 million shares (36.11% of the remaining shares) [2][7] Pricing and Payment - The issuance price is set at RMB 24.49 per share, with the online offering of 11.488 million shares scheduled for October 27, 2025 [2] - Investors must fulfill their payment obligations by October 29, 2025, with specific instructions for offline and online investors regarding payment procedures [3][4] Subscription and Allocation - The initial online subscription saw 13,647,883 valid applications, totaling 101,265,777,500 shares, resulting in an initial online winning rate of 0.01134441% [6] - Following the implementation of the allocation mechanism, the final online winning rate increased to 0.02391232% after reallocating shares from offline to online due to high demand [8] Draw and Announcement - The online draw for the issuance is scheduled for October 28, 2025, with results to be announced on October 29, 2025 [9]